abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página no está disponible en Español y está siendo mostrada en English

Artículo

14 Ago 2006

Autor:
Interfaith Center on Corporate Responsibility [USA]

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

The Interfaith Center on Corporate Responsibility released a comprehensive scorecard evaluating the pharmaceutical industry's efforts in the fight against HIV/AIDS...The ICCR report highlights the large disparities between industry best practices in addressing...HIV/AIDS...and the current actions of 15 leading pharmaceutical companies. "We see two major problems - a failure to develop new medicines that address neglected diseases and a lack of access for poor patients to the existing medicines," said Daniel Rosan, ICCR's Program Director for Public Health and author of the report... [companies rated: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Línea del tiempo